where do you get this?
Now add to that the fact that PBT2 is looking very much like it could be most effective at or before symptom onset."
PBT failed human trials several years ago then launched into PBT 2
Then they discovered they may potentially have something for Huntingtons but it won't bring in nearly as much as they would for AD, not many investors are aware
5 - 7 persons per 100,00 people are affected (1600 people have Huntingtons in Australia)
25,000 people known to suffer from Alzheimers in Australia and 1 in 10 suffer from AD in over 65 year group
How can you compare?
where do you get this? Now add to that the fact that PBT2 is...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 122248 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 25307592 | 14 |
View Market Depth
| Last trade - 16.12pm 16/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |
Day chart unavailable